Phase 2 × Recruiting × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Clear all Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Phase 2 Recruiting
50 enrolled
ALERTCML
Phase 2 Recruiting
100 enrolled
ACCELERATE
Phase 2 Recruiting
358 enrolled
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Phase 2 Recruiting
216 enrolled
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
Phase 2 Recruiting
50 enrolled
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
Phase 2 Recruiting
50 enrolled
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Phase 2 Recruiting
60 enrolled
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Phase 2 Recruiting
54 enrolled
TOKIN
Phase 2 Recruiting
100 enrolled
APTBCy
Phase 2 Recruiting
60 enrolled
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Phase 2 Recruiting
508 enrolled
Two Step Haplo With Radiation Conditioning
Phase 2 Recruiting
63 enrolled
ASC4TARGET
Phase 2 Recruiting
20 enrolled
Cord Blood Transplant in Adults With Blood Cancers
Phase 2 Recruiting
54 enrolled
Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Phase 2 Recruiting
51 enrolled
PEARL
Phase 2 Recruiting
160 enrolled
Allo HSCT Using RIC and PTCy for Hematological Diseases
Phase 2 Recruiting
56 enrolled
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 Recruiting
300 enrolled
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
Phase 2 Recruiting
20 enrolled
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
Phase 2 Recruiting
20 enrolled
MAST
Phase 2 Recruiting
50 enrolled
TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients
Phase 2 Recruiting
40 enrolled
SoraGVL
Phase 2 Recruiting
88 enrolled
VitaStem
Phase 2 Recruiting
220 enrolled